drugset / Trial / NCT00404742

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

NCT00404742

Phase 3 Completed 232 enrolled Lux Biosciences, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis

Timeline

Start
2007-01
Primary completion
2008-11
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Voclosporin Other / unclassified 0.2 mg/kg Oral
Comparator Voclosporin Other / unclassified 0.4 mg/kg Oral
Comparator Voclosporin Other / unclassified 0.6 mg/kg Oral